Stomach Cancer Market Report 2026

Stomach Cancer Market Overview

• Stomach Cancer market size has reached to $3.74 billion in 2025 • Expected to grow to $7.14 billion in 2030 at a compound annual growth rate (CAGR) of 13.8% • Growth Driver: The Rise In Helicobacter Pylori Infections Drives The Growth Of The Market Due To Its Role In Increasing Cancer Risk Through Chronic Gastric Inflammation And Poor Sanitation Conditions • Market Trend: Claudin-Targeted Cytolytic Antibody Therapy Enhancing First-Line Gastric Cancer Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Stomach Cancer Market?

Stomach cancer, also known as gastric cancer, is a disease in which malignant (cancerous) cells form in the lining of the stomach. It begins in the mucus-producing cells of the stomach’s inner layer, and can spread to deeper layers and other parts of the body. Stomach cancer often develops slowly and does not show symptoms in its early stages, but it is progresses with indigestion symptoms such as stomach pain, nausea, weight loss, and loss of appetite may appear. The main types of stomach cancer are adenocarcinoma, lymphoma, gastrointestinal stromal tumor, carcinoid tumor, and other types. Adenocarcinoma refers to a type of cancer that forms in the glandular cells lining certain internal organs and is commonly found in areas such as the stomach, lungs, prostate, and colon. It encompasses a range of therapies such as chemotherapy, targeted therapy, immunotherapy, radiation therapy, and surgical procedures. These are administered via different routes, including oral and parenteral. It is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. It caters to various end users, including hospitals and specialty clinics, ambulatory surgery centers, and others.

What Is The Stomach Cancer Market Growth Forecast?

The stomach cancer market size is expected to see rapid growth in the next few years. It will grow to $7.14 billion in 2030 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to growing adoption of precision oncology, rising investment in novel biologics, expansion of immunotherapy pipelines, increasing focus on early-stage cancer detection, improving access to advanced cancer treatments. Major trends in the forecast period include increasing adoption of targeted therapy regimens, rising use of immunotherapy combinations, growing focus on early diagnostic screening, expansion of personalized treatment approaches, enhanced integration of biomarker-based testing.

Global Stomach Cancer Market Segmentation

1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types 2) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery 3) By Route Of Administration: Oral, Parenteral 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users Subsegments: 1) By Adenocarcinoma: Intestinal Type, Diffuse Type 2) By Lymphoma: Mucosa-Associated Lymphoid Tissue Lymphoma, Diffuse Large B-Cell Lymphoma 3) By Gastrointestinal Stromal Tumor: Kit-Positive Gastrointestinal Stromal Tumor, Platelet-Derived Growth Factor Receptor Alpha-mutant Gastrointestinal Stromal, Wild-Type Gastrointestinal Stromal Tumors 4) By Carcinoid Tumor: Typical Carcinoid, Atypical Carcinoid 5) By Other Types: Squamous Cell Carcinoma, Small Cell Carcinoma, Undifferentiated Tumors

What Is The Driver Of The Stomach Cancer Market?

The rising prevalence of Helicobacter pylori infection is expected to propel the growth of the stomach cancer market going forward. Helicobacter pylori infection refers to a condition caused by the bacteria Helicobacter pylori, which colonizes the stomach lining and can lead to inflammation, ulcers, and an increased risk of stomach cancer. The rising prevalence of Helicobacter pylori infection is primarily due to poor sanitation, which facilitates the fecal-oral and oral-oral transmission of the bacteria in overcrowded or unhygienic living conditions. Helicobacter pylori infection drives stomach cancer by causing chronic inflammation and cellular damage in the stomach lining, leading to precancerous changes and tumor development. For instance, in November 2024, according to the Government of Canada, a Canada-based government agency, the recurrence rate of Helicobacter pylori infection was 19% in 2023, with the rate varying based on factors such as geographic location and age group. Therefore, the rising prevalence of Helicobacter pylori infection is driving the growth of the stomach cancer industry.

Key Players In The Global Stomach Cancer Market

Major companies operating in the stomach cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Amgen Inc, Daiichi Sankyo Company Limited, BeiGene Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Zai Lab Limited, MacroGenics Inc., Astellas Pharma Inc., Ipsen Group, AbbVie Inc., Bayer AG, Ono Pharmaceutical Co. Ltd.

Global Stomach Cancer Market Trends and Insights

Major companies operating in the stomach cancer treatment market are focusing on developing advanced solutions such as claudin (CLDN18.2)-targeted cytolytic antibody therapy to enhance precision in first-line therapies for HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma. Claudin (CLDN18.2)-targeted cytolytic antibody therapy involves a monoclonal antibody designed to selectively bind to CLDN18.2-expressing tumor cells and induce cytotoxic effects when combined with chemotherapy, improving both progression-free and overall survival outcomes. For instance, in October 2024, Astellas Pharma US, Inc., a Japan-based pharmaceutical company, launched Vyloy (zolbetuximab-clzb), a claudin (CLDN18.2)-directed cytolytic antibody for gastric and gastroesophageal junction (GEJ) cancer treatment. It is an innovative biologic therapy administered intravenously alongside fluoropyrimidine- and platinum-containing chemotherapy, offering a median progression-free survival benefit of up to 10.6 months and overall survival of up to 18.2 months in clinical trials. This therapy selectively targets CLDN18.2-positive cancer cells, reduces off-target toxicity, and increases treatment specificity, marking a significant advancement in personalized oncology for advanced gastric cancer.

What Are Latest Mergers And Acquisitions In The Stomach Cancer Market?

In February 2025, GSK plc., a UK-based pharmaceutical company, acquired IDRx, Inc., for $1.15 billion. Through this acquisition, GSK plc aims to strengthen its oncology pipeline by advancing innovative targeted therapies for cancer treatment. IDRx, Inc. is a US-based biopharmaceutical company that specializes in discovering and developing precision oncology therapies targeting specific genetic mutations in cancer.

Regional Outlook

North America was the largest region in the stomach cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Stomach Cancer Market?

The stomach cancer market consists of revenues earned by entities by providing services such as diagnostic services, surgical services, post-treatment monitoring and palliative care, genetic and biomarker testing, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. The stomach cancer market also includes sales of diagnostic tools and kits, surgical instruments and devices, companion diagnostics, supportive care medications, and biomarker testing kits. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Stomach Cancer Market Report 2026?

The stomach cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the stomach cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.